LncRNA SCAMP1 disrupts the balance between miR-26a-5p and ZEB2 to promote osteosarcoma cell viability and invasion

Li, Rong; Chen, Zhe; Zhou, Yubo; Maimaitirexiati, Gulikezi; Yan, Qi; Li, Yuting; Maimaitiyimin, Adilijiang; Zhou, Chuangbing; Ren, Jingqin; Liu, Chengqing; Mainike, Abasi; Zhou, Peng; Ding, Liang

doi:10.3389/fonc.2022.967000

Cited by 5 publications

(6 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both pathways are involved in OS progression [ 15 , 16 ]. ZEB2 is involved in epithelial-mesenchymal transition (EMT) and may play a role in OS metastasis[ 17 ]. The roles of ZNF471, ALX4, and ZNF655 in OS are unknown.…”

Section: Resultsmentioning

confidence: 99%

SOX9 is a key component of RUNX2-regulated transcriptional circuitry in osteosarcoma

Kim¹,

Tseng²,

Ayaz³

et al. 2023

Cell Biosci

View full text Add to dashboard Cite

Background The absence of prominent, actionable genetic alternations in osteosarcomas (OS) implies that transcriptional and epigenetic mechanisms significantly contribute to the progression of this life-threatening form of cancer. Therefore, the identification of potential transcriptional events that promote the survival of OS cells could be key in devising targeted therapeutic approaches for OS. We have previously shown that RUNX2 is a transcription factor (TF) essential for OS cell survival. Unfortunately, the transcriptional network or circuitry regulated by RUNX2 in OS cells is still largely unknown. Methods The TFs that are in the RUNX2 transcriptional circuitry were identified by analyzing RNAseq and ChIPseq datasets of RUNX2. To evaluate the effect of SOX9 knockdown on the survival of osteosarcoma cells in vitro, we employed cleaved caspase-3 immunoblotting and propidium iodide staining techniques. The impact of SOX9 and JMJD1C depletion on OS tumor growth was examined in vivo using xenografts and immunohistochemistry. Downstream targets of SOX9 were identified and dissected using RNAseq, pathway analysis, and gene set enrichment analysis. Furthermore, the interactome of SOX9 was identified using BioID and validated by PLA. Result Our findings demonstrate that SOX9 is a critical TF that is induced by RUNX2. Both in vitro and in vivo experiments revealed that SOX9 plays a pivotal role in the survival of OS. RNAseq analysis revealed that SOX9 activates the transcription of MYC, a downstream target of RUNX2. Mechanistically, our results suggest a transcriptional network involving SOX9, RUNX2, and MYC, with SOX9 binding to RUNX2. Moreover, we discovered that JMJD1C, a chromatin factor, is a novel binding partner of SOX9, and depletion of JMJD1C impairs OS tumor growth. Conclusion The findings of this study represent a significant advancement in our understanding of the transcriptional network present in OS cells, providing valuable insights that may contribute to the development of targeted therapies for OS.

show abstract

Section: Resultsmentioning

confidence: 99%

SOX9 is a key component of RUNX2-regulated transcriptional circuitry in osteosarcoma

Kim¹,

Tseng²,

Ayaz³

et al. 2023

Cell Biosci

View full text Add to dashboard Cite

show abstract

“…LncRNA EBLN3P regulated the expression of O-GlcNAc pathway via sponging miR-200a-3p, leading to methotrexate resistance in osteosarcoma cells 46 . Our previous study showed that lncRNA SCAMP1 regulated miR-26a-5p and ZEB2, contributing to promotion of cell invasion and viability in osteosarcoma 47 . These findings suggested that lncRNAs are involved in osteosarcoma development and progression.…”

Section: Discussionmentioning

confidence: 95%

“…1 µg of RNA was used to obtain cDNA via reverse transcription. PCR was performed by SYBR Green Kit as described before 47 . The expression of GAPDH was for normalization.…”

Section: Methodsmentioning

confidence: 99%

LncRNA HOXA-AS3 promotes cell proliferation and invasion via targeting miR-218-5p/FOXP1 axis in osteosarcoma

Li,

Chen,

Zhou

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Osteosarcoma is an aggressive form of bone cancer and affects the health in children and adolescents. Although conventional treatment improves the osteosarcoma survival, some patients have metastasis and drug resistance, leading to a worse prognosis. Therefore, it is necessary to explore the molecular mechanism of osteosarcoma occurrence and progression, which could discover the novel treatment for osteosarcoma. Long noncoding RNAs (lncRNAs) have been reported to regulate osteosarcoma occurrence and malignant progression. LncRNA HOXA-AS3 facilitates the tumorigenesis and progression in a variety of human cancers. However, the underlying mechanism of lncRNA HOXA-AS3-induced oncogenesis is poorly determined in osteosarcoma. To address this point, we utilized several cellular biological strategies and molecular approaches to explore the biological functions and mechanisms of lncRNA HOXA-AS3 in osteosarcoma cells. We found that lncRNA HOXA-AS3 facilitates cell proliferation and invasion via targeting miR-218-5p/FOXP1 axis in osteosarcoma. In conclusion, lncRNA HOXA-AS3 could be a promising target for osteosarcoma treatment.

show abstract

“…Secretory carrier membrane protein 1 (SCAMP1) is a lncRNA that promotes cancer progression through cell viability and invasion [75]. The SCAMP1 variant 2 (SCAMP1-TV2) shows increased expression in BC tumors from both LumA and TNBC subtypes and in several human BC cell lines, where SCAMP1-TV2 silencing promotes decreased levels of PI3K and AKT, both phosphorylated and unphosphorylated forms.…”

Section: Norad Higher In Low Cd8 T-cell Count; the Promotion Of Malig...mentioning

confidence: 99%

NORAD-Regulated Signaling Pathways in Breast Cancer Progression

Capela,

Tavares-Marcos,

Estima-Arede

et al. 2024

Cancers

View full text Add to dashboard Cite

Long non-coding RNA activated by DNA damage (NORAD) has recently been associated with pathologic mechanisms underlying cancer progression. Due to NORAD’s extended range of interacting partners, there has been contradictory data on its oncogenic or tumor suppressor roles in BC. This review will summarize the function of NORAD in different BC subtypes and how NORAD impacts crucial signaling pathways in this pathology. Through the preferential binding to pumilio (PUM) proteins PUM1 and PUM2, NORAD has been shown to be involved in the control of cell cycle, angiogenesis, mitosis, DNA replication and transcription and protein translation. More recently, NORAD has been associated with PUM-independent roles, accomplished by interacting with other ncRNAs, mRNAs and proteins. The intricate network of NORAD-mediated signaling pathways may provide insights into the potential design of novel unexplored strategies to overcome chemotherapy resistance in BC treatment.

show abstract

LncRNA SCAMP1 disrupts the balance between miR-26a-5p and ZEB2 to promote osteosarcoma cell viability and invasion

Cited by 5 publications

References 41 publications

SOX9 is a key component of RUNX2-regulated transcriptional circuitry in osteosarcoma

SOX9 is a key component of RUNX2-regulated transcriptional circuitry in osteosarcoma

LncRNA HOXA-AS3 promotes cell proliferation and invasion via targeting miR-218-5p/FOXP1 axis in osteosarcoma

NORAD-Regulated Signaling Pathways in Breast Cancer Progression

Contact Info

Product

Resources

About